Amylyx Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 384
- Market Cap
- $145M
- Website
- http://www.amylyx.com
Avexitide for Treatment of Post-Bariatric Hypoglycemia
- Conditions
- Post Bariatric Hypoglycemia
- Interventions
- Other: PlaceboDrug: Avexitide
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Amylyx Pharmaceuticals Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06747468
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
- Conditions
- ALS
- Interventions
- Drug: AMX0114Other: Placebo
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Amylyx Pharmaceuticals Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06665165
AMX0035 and Progressive Supranuclear Palsy
- Conditions
- Neurodegenerative DiseasesAtypical ParkinsonismPSPProgressive Supranuclear Palsy
- Interventions
- Drug: AMX0035Other: Placebo
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Amylyx Pharmaceuticals Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06122662
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Parkinson's & Movement Disorder Institute, Fountain Valley, California, United States
AMX0035 in Adult Patients With Wolfram Syndrome
- Conditions
- Wolfram Syndrome
- Interventions
- Drug: AMX0035
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Amylyx Pharmaceuticals Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05676034
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
Extension Study Evaluating The Safety And Tolerability of AMX0035
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: AMX0035
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Amylyx Pharmaceuticals Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT05619783
- Locations
- 🇮🇹
University of Milan Medical School, Milan, Italy
🇮🇹Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
🇫🇷Hospices Civils de Lyon Hôpital Neurologique Pierre Wertheimer Cellule Mutualisée de Recherche Clinique (CMRC), Bron, France
An Intermediate Size Expanded Access Protocol of AMX0035 for ALS
- Conditions
- Amyotrophic Lateral Sclerosis
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Amylyx Pharmaceuticals Inc.
- Registration Number
- NCT05286372
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Nova Southeastern University, Fort Lauderdale, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Other: PlaceboDrug: AMX0035
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Amylyx Pharmaceuticals Inc.
- Target Recruit Count
- 664
- Registration Number
- NCT05021536
- Locations
- 🇺🇸
Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Johns Hopkins University School of Medicine Outpatient Center, Baltimore, Maryland, United States
Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS
- Conditions
- ALS
- Interventions
- Drug: AMX0035
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Amylyx Pharmaceuticals Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04987671
- Locations
- 🇺🇸
Norman Fixel Institute for Neurological Diseases, Gainesville, Florida, United States
A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: AMX0035
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Amylyx Pharmaceuticals Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04516096
- Locations
- 🇺🇸
University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Forbes Norris MDA/ALS Research Center - California Pacific Medical Center, San Francisco, California, United States
Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Interventions
- Drug: AMX0035Drug: Placebo
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Amylyx Pharmaceuticals Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT03533257
- Locations
- 🇺🇸
University of Kansas Clinical Research Center, Fairway, Kansas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Penn Memory Center, Philadelphia, Pennsylvania, United States